Management of hepatitis C virus infection recurrence after liver transplantation: an overview. (Q37844982)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

review article

1 reference

title

Management of hepatitis C virus infection recurrence after liver transplantation: an overview (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

Francesca Romana Ponziani

23 January 2020

main subject

liver transplantation

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

Maurizio Pompili

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

Patrizia Burra

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

author name string

A Gasbarrini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

S Fagiuoli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

Transplantation Proceedings

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

291-295

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21335208 AND SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Evolution of hepatitis C virus in liver allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Antiviral therapy for hepatitis C in the setting of liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Preemptive therapy for hepatitis C virus after living-donor liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Review article: the treatment of hepatitis C virus recurrence after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Therapeutic management of recurrent hepatitis C after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treating chronic hepatitis C virus after liver transplantation: balancing the risks against the chance for success

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Approach to recurrent hepatitis C following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Managing chronic hepatitis C in the difficult-to-treat patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Recurrent disease after liver transplantation. A therapeutic dilemma or treatable?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Outcomes of acute rejection after interferon therapy in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Recurrent allograft HCV presenting as acute cellular rejection: successful management with interferon and ribavirin alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Ribavirin and interferon for recurrent posttransplantation HCV infection: To treat or not to treat?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Aspects of hepatitis C virus infection relating to liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment of hepatitis C virus infection in the allograft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Daily interferon Alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Combination therapy for hepatitis C virus reinfection after orthoptic liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Natural alpha-IFN in HCV recurrence after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Posttransplantation prevention and treatment of recurrent hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Combination of interferon-alpha and ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Relapse response to interferon and ribavirin in liver transplant recipient with hepatitis C recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase cha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102

Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.09.102